Patoloxía Molecular das Doenzas Raras
PatMol-DR
Hospital Vall d'Hebron
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Vall d'Hebron (33)
2024
-
Ramipril After Transcatheter Aortic Valve Implantation in Patients Without Reduced Ejection Fraction: The RASTAVI Randomized Clinical Trial
Journal of the American Heart Association, Vol. 13, Núm. 19, pp. e035460
2023
-
Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care
Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269
-
Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease
Nefrologia, Vol. 43, Núm. 4, pp. 386-398
-
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis
Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75
2022
-
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry
European Journal of Clinical Investigation, Vol. 52, Núm. 12
-
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry
Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529
2021
-
Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)
Basic Research in Cardiology, Vol. 116, Núm. 1
2020
-
Reducing residual thrombotic risk in patients with peripheral artery disease: Impact of the COMPASS trial
Drugs in Context, Vol. 9
-
Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition
Expert Review of Clinical Pharmacology, Vol. 13, Núm. 7, pp. 695-706
2019
-
Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors
Revista Espanola de Cardiologia
2018
-
Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial
European Heart Journal, Vol. 39, Núm. 15, pp. 1255-1264
-
Transición desde la asistencia pediátrica a la adulta en pacientes con mucopolisacaridosis
Revista Clinica Espanola, Vol. 218, Núm. 1, pp. 17-21
2017
-
Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis
Molecular Genetics and Metabolism, Vol. 121, Núm. 2, pp. 138-149
2016
-
Change of concept about the regulation of angiotensin II-induced monocyte chemoattractant protein-1 production in human endothelial cells
Vascular Pharmacology, Vol. 80, pp. 20-34
-
Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study
Revista Espanola de Cardiologia, Vol. 69, Núm. 10, pp. 931-938
-
Insuficiente control de parámetros lipídicos en pacientes con enfermedad coronaria: un problema por resolver. Respuesta
Revista Espanola de Cardiologia
-
Necesidades no cubiertas con el tratamiento hipolipemiante oral: documento de posición de la Sociedad Española de Cardiología
Revista Espanola de Cardiologia, Vol. 69, Núm. 11, pp. 1083-1087
-
Proceso de transición de la asistencia pediátrica a la adulta en pacientes con errores congénitos del metabolismo. Documento de consenso
Medicina Clinica, Vol. 147, Núm. 11, pp. 506.e1-506.e7
-
Tendencias en factores de riesgo y tratamientos de pacientes con cardiopatía isquémica estable atendidos en consultas de cardiología entre 2006 y 2014
Revista Espanola de Cardiologia, Vol. 69, Núm. 4, pp. 401-407
2015
-
Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome
Biomarkers in Medicine, Vol. 9, Núm. 3, pp. 209-216